DCs activated with mRNA or protein encodes/incorporates a diversified repertoire of tumor epitopes elicit MHC class I- and II- biased immunity respectively, which eventually leads to a differential activation preference for CD8+ T and CD4+ T cells 36. The gene discussed is CD4; the disease is neoplasm.